SEQUA.BR
Sequana Medical NV [SEQUA.BR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SEQUA.BR Stock Summary
Top 10 Correlated Stocks
SEQUA.BR
In the News
SEQUA.BR Financial details
Company Rating
-
Market Cap
45.37M
Income
-56.7M
Revenue
1.36M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
70
Optionable
No
Shortable
Yes
Earnings
05 Sep 2024
P/E
-3.12
Forward P/E
-
PEG
-0.48
P/S
129.17
P/B
-44.62
P/C
-
P/FCF
-4.23
Quick Ratio
1.25
Current Ratio
1.52
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.22
EPS next Y
-
EPS next Q
-
EPS this Y
-9.63%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
0%
Revenue last 5Y
-6.01%
Revenue Q/Q
-14.67%
EPS Q/Q
-12.31%
-
-
-
-
SMA20
0.97%
SMA50
-40.57%
SMA100
42.47%
Inst Own
-
Inst Trans
-
ROA
-118%
ROE
2093%
ROC
-2.61%
Gross Margin
78%
Oper. Margin
-3077%
Profit Margin
-3334%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.36-5.18
52W High
-80.2%
52W Low
-1%
RSI
43.95
Rel Volume
1.49
Avg Volume
108.07K
Volume
160.52K
Perf Week
-5.71%
Perf Month
-37.74%
Perf Quarter
10%
Perf Half Y
2.06%
-
-
-
-
Beta
0.834
-
-
Volatility
0.03%, 0.14%
Prev Close
-1%
Price
0.99
Change
-1%
Company Profile
- Volume Average 108.07K
- Market Capitalization 45.37M
- Employee 70
- CEO Mr. Ian Crosbie
- Headquarters Gent,BE
- IPO Date 2019-02-11
-
Website
https://www.sequanamedical.com 
Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.
